[{"id":"0ed50171-eed5-449a-810c-57f1bdbbcb80","acronym":"OFSET","url":"https://clinicaltrials.gov/study/NCT05879926","created_at":"2023-05-30T14:05:14.431Z","updated_at":"2025-02-25T16:55:01.814Z","phase":"Phase 3","brief_title":"Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25","source_id_and_acronym":"NCT05879926 - OFSET","lead_sponsor":"NRG Oncology","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 negative • PGR positive","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e triptorelin • goserelin acetate"],"overall_status":"Recruiting","enrollment":" Enrollment 3960","initiation":"Initiation: 08/31/2023","start_date":" 08/31/2023","primary_txt":" Primary completion: 01/01/2032","primary_completion_date":" 01/01/2032","study_txt":" Completion: 07/01/2034","study_completion_date":" 07/01/2034","last_update_posted":"2025-02-04"},{"id":"ac946163-6425-4f9a-8c1e-f35619d318be","acronym":"ROSE","url":"https://clinicaltrials.gov/study/NCT05377684","created_at":"2022-05-17T11:53:45.438Z","updated_at":"2025-02-25T17:25:34.281Z","phase":"","brief_title":"Study of Quality of Life and Hormone Levels in Premenopausal Participants With Early Breast Cancer Receiving Triptorelin Plus Additional Cancer Treatment","source_id_and_acronym":"NCT05377684 - ROSE","lead_sponsor":"Ipsen","biomarkers":" HER-2 • BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" HR positive • HER-2 negative • HR positive + HER-2 negative • BRCA mutation","tags":["HER-2 • BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • HR positive + HER-2 negative • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e triptorelin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 450","initiation":"Initiation: 06/09/2022","start_date":" 06/09/2022","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2025-01-31"},{"id":"f65dd733-9008-4681-bf13-626c30073cdc","acronym":"SAFIR 03","url":"https://clinicaltrials.gov/study/NCT05625087","created_at":"2022-11-22T15:59:03.927Z","updated_at":"2025-02-25T15:54:42.995Z","phase":"Phase 2","brief_title":"Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib","source_id_and_acronym":"NCT05625087 - SAFIR 03","lead_sponsor":"UNICANCER","biomarkers":" HER-2 • ER • PIK3CA • PGR","pipe":" | ","alterations":" HR positive • HER-2 overexpression • HER-2 negative • PIK3CA mutation • HER-2 overexpression + HR positive","tags":["HER-2 • ER • PIK3CA • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 overexpression • HER-2 negative • PIK3CA mutation • HER-2 overexpression + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Piqray (alpelisib) • Kisqali (ribociclib) • fulvestrant • triptorelin"],"overall_status":"Recruiting","enrollment":" Enrollment 162","initiation":"Initiation: 10/19/2023","start_date":" 10/19/2023","primary_txt":" Primary completion: 07/01/2028","primary_completion_date":" 07/01/2028","study_txt":" Completion: 06/01/2030","study_completion_date":" 06/01/2030","last_update_posted":"2025-01-30"},{"id":"d08e3cfd-4eeb-458a-9218-3225ed8135e4","acronym":"NePtune","url":"https://clinicaltrials.gov/study/NCT05498272","created_at":"2022-09-18T06:19:44.875Z","updated_at":"2025-02-25T15:00:34.026Z","phase":"Phase 2","brief_title":"Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations","source_id_and_acronym":"NCT05498272 - NePtune","lead_sponsor":"Rana McKay, MD","biomarkers":" BRCA1 • BRCA2","pipe":"","alterations":" ","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • triptorelin • goserelin acetate • leuprolide acetate for depot suspension"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 02/01/2023","start_date":" 02/01/2023","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-10-24"},{"id":"cf8bf0b5-ca6f-4f6e-a44f-54ab88c53b60","acronym":"FACILE","url":"https://clinicaltrials.gov/study/NCT03944434","created_at":"2021-01-18T19:25:17.328Z","updated_at":"2025-02-25T15:43:30.551Z","phase":"Phase 2","brief_title":"FACILE: FeAsibility of First-line riboCIclib in oLdEr Patients With Advanced Breast Cancer","source_id_and_acronym":"NCT03944434 - FACILE","lead_sponsor":"Fondazione Sandro Pitigliani","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kisqali (ribociclib) • letrozole • anastrozole • triptorelin • goserelin acetate • leuprolide acetate for depot suspension"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 116","initiation":"Initiation: 12/27/2018","start_date":" 12/27/2018","primary_txt":" Primary completion: 12/27/2024","primary_completion_date":" 12/27/2024","study_txt":" Completion: 11/27/2025","study_completion_date":" 11/27/2025","last_update_posted":"2024-09-25"},{"id":"63ba93fd-a0f6-4865-ad2d-03267b454c0a","acronym":"S1802","url":"https://clinicaltrials.gov/study/NCT03678025","created_at":"2021-07-05T17:17:10.086Z","updated_at":"2025-02-25T16:31:34.107Z","phase":"Phase 3","brief_title":"Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer","source_id_and_acronym":"NCT03678025 - S1802","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" SYP","pipe":"","alterations":" ","tags":["SYP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • abiraterone acetate • prednisone • Eligard (leuprolide acetate) • bicalutamide • triptorelin • goserelin acetate • flutamide • nilutamide • Firmagon (degarelix) • Viadur (leuprorelin implant)"],"overall_status":"Recruiting","enrollment":" Enrollment 1273","initiation":"Initiation: 09/24/2018","start_date":" 09/24/2018","primary_txt":" Primary completion: 04/01/2028","primary_completion_date":" 04/01/2028","study_txt":" Completion: 10/01/2031","study_completion_date":" 10/01/2031","last_update_posted":"2024-08-16"},{"id":"4004e195-6fa4-408f-8f56-450ccd6489c0","acronym":"","url":"https://clinicaltrials.gov/study/NCT06528210","created_at":"2025-02-25T16:02:53.341Z","updated_at":"2025-02-25T16:02:53.341Z","phase":"Phase 2","brief_title":"Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer","source_id_and_acronym":"NCT06528210","lead_sponsor":"OHSU Knight Cancer Institute","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • bicalutamide • triptorelin • goserelin acetate • Firmagon (degarelix) • Orgovyx (relugolix) • leuprolide acetate for depot suspension"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 08/01/2024","start_date":" 08/01/2024","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2028","study_completion_date":" 06/01/2028","last_update_posted":"2024-07-30"},{"id":"75f0b64e-2f38-4d3f-986a-4f0367fd8684","acronym":"BOUQUET","url":"https://clinicaltrials.gov/study/NCT04931342","created_at":"2022-05-03T17:53:37.321Z","updated_at":"2024-07-02T16:34:26.433Z","phase":"Phase 2","brief_title":"A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors","source_id_and_acronym":"NCT04931342 - BOUQUET","lead_sponsor":"Hoffmann-La Roche","biomarkers":" ER","pipe":"","alterations":" ","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Lynparza (olaparib) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • paclitaxel • Kadcyla (ado-trastuzumab emtansine) • Cotellic (cobimetinib) • Verzenio (abemaciclib) • cyclophosphamide • letrozole • ipatasertib (RG7440) • triptorelin • goserelin acetate • Itovebi (inavolisib) • giredestrant (RG6171)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 176","initiation":"Initiation: 10/07/2021","start_date":" 10/07/2021","primary_txt":" Primary completion: 05/30/2028","primary_completion_date":" 05/30/2028","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2024-06-13"},{"id":"469f79f5-7bed-470f-bde8-dd6a3a9d7203","acronym":"GO39932","url":"https://clinicaltrials.gov/study/NCT03332797","created_at":"2021-01-17T18:03:30.772Z","updated_at":"2024-07-02T16:34:37.744Z","phase":"Phase 1","brief_title":"A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer","source_id_and_acronym":"NCT03332797 - GO39932","lead_sponsor":"Genentech, Inc.","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 positive • ER positive • HER-2 negative • ER positive + HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER positive • HER-2 negative • ER positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • triptorelin • goserelin acetate • giredestrant (RG6171)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 181","initiation":"Initiation: 11/27/2017","start_date":" 11/27/2017","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-06-06"},{"id":"f959eeb0-3b0b-4ca2-b45f-49dbe8ed0379","acronym":"PREcoopERA","url":"https://clinicaltrials.gov/study/NCT05896566","created_at":"2023-06-09T16:06:48.058Z","updated_at":"2024-07-02T16:35:11.267Z","phase":"Phase 2","brief_title":"A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer","source_id_and_acronym":"NCT05896566 - PREcoopERA","lead_sponsor":"ETOP IBCSG Partners Foundation","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e anastrozole • triptorelin • giredestrant (RG6171)"],"overall_status":"Recruiting","enrollment":" Enrollment 220","initiation":"Initiation: 01/23/2024","start_date":" 01/23/2024","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2024-04-05"},{"id":"774e2276-9e3e-4c25-a260-4a11c73a7ed3","acronym":"SOLTI-2104","url":"https://clinicaltrials.gov/study/NCT05982093","created_at":"2023-08-08T14:08:42.597Z","updated_at":"2024-07-02T16:35:19.531Z","phase":"Phase 2","brief_title":"Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer","source_id_and_acronym":"NCT05982093 - SOLTI-2104","lead_sponsor":"SOLTI Breast Cancer Research Group","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HER-2 negative • HER-2 expression","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Orserdu (elacestrant) • triptorelin"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 10/03/2023","start_date":" 10/03/2023","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-02-13"},{"id":"1bd14822-da3c-4dbb-9782-85f6d5deab4b","acronym":"PREDICT-RT","url":"https://clinicaltrials.gov/study/NCT04513717","created_at":"2021-01-18T21:37:58.373Z","updated_at":"2024-07-02T16:35:20.440Z","phase":"Phase 3","brief_title":"Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial","source_id_and_acronym":"NCT04513717 - PREDICT-RT","lead_sponsor":"NRG Oncology","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate • bicalutamide • apalutamide • triptorelin • goserelin acetate • flutamide • Firmagon (degarelix) • leuprolide acetate for depot suspension • Suprefact (buserelin acetate) • Yonsa (abiraterone acetate)"],"overall_status":"Recruiting","enrollment":" Enrollment 2478","initiation":"Initiation: 12/15/2020","start_date":" 12/15/2020","primary_txt":" Primary completion: 12/31/2033","primary_completion_date":" 12/31/2033","study_txt":" Completion: 12/31/2033","study_completion_date":" 12/31/2033","last_update_posted":"2024-02-07"},{"id":"77650eab-43cf-4fc1-b1f7-8de4c87fdc86","acronym":"TEXT","url":"https://clinicaltrials.gov/study/NCT00066703","created_at":"2021-01-18T00:09:39.799Z","updated_at":"2024-07-02T16:35:24.835Z","phase":"Phase 3","brief_title":"Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer","source_id_and_acronym":"NCT00066703 - TEXT","lead_sponsor":"ETOP IBCSG Partners Foundation","biomarkers":" PGR","pipe":" | ","alterations":" HR positive • PGR positive","tags":["PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • exemestane • triptorelin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 2672","initiation":"Initiation: 11/03/2003","start_date":" 11/03/2003","primary_txt":" Primary completion: 03/11/2011","primary_completion_date":" 03/11/2011","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-01-01"},{"id":"d6b8d28f-cf57-448e-abf6-4ebc22b10127","acronym":"SOFT","url":"https://clinicaltrials.gov/study/NCT00066690","created_at":"2021-01-18T00:09:39.396Z","updated_at":"2024-07-02T16:35:24.866Z","phase":"Phase 3","brief_title":"Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer","source_id_and_acronym":"NCT00066690 - SOFT","lead_sponsor":"ETOP IBCSG Partners Foundation","biomarkers":" ER • PGR","pipe":" | ","alterations":" HR positive","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e exemestane • triptorelin • Soltamox (tamoxifen citrate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 3066","initiation":"Initiation: 12/17/2003","start_date":" 12/17/2003","primary_txt":" Primary completion: 05/01/2014","primary_completion_date":" 05/01/2014","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-01-01"},{"id":"0f494b10-c7de-444c-8668-530d6e3b1c05","acronym":"Trace-II","url":"https://clinicaltrials.gov/study/NCT05555017","created_at":"2022-09-26T14:56:17.853Z","updated_at":"2024-07-02T16:35:34.518Z","phase":"Phase 2","brief_title":"Tracer-Guided Surgery for Recurrent Prostate Cancer","source_id_and_acronym":"NCT05555017 - Trace-II","lead_sponsor":"The Netherlands Cancer Institute","biomarkers":" FOLH1","pipe":" | ","alterations":" FOLH1 expression","tags":["FOLH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLH1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e triptorelin"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 02/15/2023","start_date":" 02/15/2023","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2023-10-06"},{"id":"4415345d-a697-4291-8d70-7d0798eb8ec4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05945407","created_at":"2023-07-14T18:08:53.504Z","updated_at":"2024-07-02T16:35:42.902Z","phase":"","brief_title":"Fertility-sparing Therapy for Patients With Stage IA Endometrial Cancer","source_id_and_acronym":"NCT05945407","lead_sponsor":"Peking University People's Hospital","biomarkers":" TP53 • PTEN • MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" TP53 expression","tags":["TP53 • PTEN • MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e triptorelin • goserelin acetate • megestrol"],"overall_status":"Recruiting","enrollment":" Enrollment 57","initiation":"Initiation: 08/01/2016","start_date":" 08/01/2016","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2023-07-14"},{"id":"8a3b861b-e6d7-4999-9657-66fbacd7d7d6","acronym":"TEXT-Bone","url":"https://clinicaltrials.gov/study/NCT00963417","created_at":"2021-01-18T03:45:06.718Z","updated_at":"2024-07-02T16:35:46.911Z","phase":"","brief_title":"Study of Bone Mineral Density in Women With Breast Cancer Treated With Triptorelin and Tamoxifen or Exemestane on Protocol IBCSG 25-02","source_id_and_acronym":"NCT00963417 - TEXT-Bone","lead_sponsor":"ETOP IBCSG Partners Foundation","biomarkers":" IGF1 • IGFBP3","pipe":" | ","alterations":" HR positive","tags":["IGF1 • IGFBP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • exemestane • triptorelin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 119","initiation":"Initiation: 08/03/2009","start_date":" 08/03/2009","primary_txt":" Primary completion: 03/11/2011","primary_completion_date":" 03/11/2011","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-05-31"},{"id":"3d7d1f47-fe60-4cd7-84c9-27097e2149d6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05801705","created_at":"2023-04-06T14:03:22.107Z","updated_at":"2024-07-02T16:35:47.680Z","phase":"","brief_title":"Comparative Evaluation of Efficacy and Safety of Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian Function Suppression in Hormone Receptor-Positive Early Breast Cancer Among Non-Low-Risk Premenopausal Women: A Real-World Study","source_id_and_acronym":"NCT05801705","lead_sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HR positive • HER-2 overexpression • HER-2 amplification • PGR positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 overexpression • HER-2 amplification • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • triptorelin • goserelin acetate"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 700","initiation":"Initiation: 06/01/2023","start_date":" 06/01/2023","primary_txt":" Primary completion: 06/30/2023","primary_completion_date":" 06/30/2023","study_txt":" Completion: 12/30/2023","study_completion_date":" 12/30/2023","last_update_posted":"2023-05-18"},{"id":"bd0e88db-137f-4853-9790-1eb870c8605e","acronym":"NEMO","url":"https://clinicaltrials.gov/study/NCT05800197","created_at":"2023-04-05T14:03:37.358Z","updated_at":"2024-07-02T16:35:51.305Z","phase":"","brief_title":"Neoadjuvant Endocrine Therapy in Breast Cancer. Real Clinical Practice in Russia","source_id_and_acronym":"NCT05800197 - NEMO","lead_sponsor":"Blokhin's Russian Cancer Research Center","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • letrozole • anastrozole • triptorelin • goserelin acetate"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 04/15/2014","start_date":" 04/15/2014","primary_txt":" Primary completion: 08/15/2023","primary_completion_date":" 08/15/2023","study_txt":" Completion: 01/15/2025","study_completion_date":" 01/15/2025","last_update_posted":"2023-04-06"},{"id":"69a6fb49-a8b9-43df-9af8-05036660346a","acronym":"HOBOE","url":"https://clinicaltrials.gov/study/NCT00412022","created_at":"2021-01-18T01:26:47.797Z","updated_at":"2024-07-02T16:35:52.374Z","phase":"Phase 3","brief_title":"HOBOE: A Phase 3 Study of Adjuvant Triptorelin and Tamoxifen, Letrozole, or Letrozole and Zoledronic Acid in Premenopausal Patients With Breast Cancer.","source_id_and_acronym":"NCT00412022 - HOBOE","lead_sponsor":"National Cancer Institute, Naples","biomarkers":" PGR","pipe":" | ","alterations":" PGR positive","tags":["PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • letrozole • triptorelin • zoledronic acid"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1294","initiation":"Initiation: 03/01/2004","start_date":" 03/01/2004","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 11/01/2024","study_completion_date":" 11/01/2024","last_update_posted":"2023-03-24"},{"id":"5407fb3b-d007-4f1e-a554-6a2db8ecb89a","acronym":"PROMETEO II","url":"https://clinicaltrials.gov/study/NCT04130152","created_at":"2021-01-18T20:10:33.971Z","updated_at":"2024-07-02T16:36:01.915Z","phase":"Phase 1","brief_title":"Palbociclib Plus Letrozole in Hormone Receptor Positive Residual Disease After Neoadjuvant Chemotherapy","source_id_and_acronym":"NCT04130152 - PROMETEO II","lead_sponsor":"SOLTI Breast Cancer Research Group","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 positive • ER positive • HR positive • HER-2 negative • PGR positive • HR positive + HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER positive • HR positive • HER-2 negative • PGR positive • HR positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • letrozole • triptorelin"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 11/21/2019","start_date":" 11/21/2019","primary_txt":" Primary completion: 01/26/2022","primary_completion_date":" 01/26/2022","study_txt":" Completion: 02/24/2022","study_completion_date":" 02/24/2022","last_update_posted":"2022-10-25"},{"id":"0b63362f-4ed6-4b42-aae6-d28bb107156e","acronym":"SOFT-EST","url":"https://clinicaltrials.gov/study/NCT00975676","created_at":"2021-01-18T03:48:15.006Z","updated_at":"2024-07-02T16:36:22.522Z","phase":"","brief_title":"Study of Estrogen Levels in Premenopausal Women Who Have Undergone Surgery for Breast Cancer and Are Receiving Triptorelin and Tamoxifen Citrate or Exemestane on Clinical Trial IBCSG 24-02","source_id_and_acronym":"NCT00975676 - SOFT-EST","lead_sponsor":"ETOP IBCSG Partners Foundation","biomarkers":" ER • PGR","pipe":" | ","alterations":" PGR positive","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • exemestane • triptorelin • Soltamox (tamoxifen citrate)"],"overall_status":"Completed","enrollment":" Enrollment 123","initiation":"Initiation: 11/25/2008","start_date":" 11/25/2008","primary_txt":" Primary completion: 12/01/2016","primary_completion_date":" 12/01/2016","study_txt":" Completion: 12/01/2016","study_completion_date":" 12/01/2016","last_update_posted":"2021-10-25"},{"id":"c1ca6546-82ac-477f-9910-2f302ab088e3","acronym":"","url":"https://clinicaltrials.gov/study/NCT04753177","created_at":"2021-02-15T14:57:58.924Z","updated_at":"2024-07-02T16:36:34.634Z","phase":"Phase 2/3","brief_title":"The Neoadjuvant Combined Hormone Therapy in Premenopausal Women With Locally Advanced ER+/HER2- Breast Cancer","source_id_and_acronym":"NCT04753177","lead_sponsor":"Saint Petersburg State Budgetary Healthcare Institution, City Clinical Oncology Dispensary","biomarkers":" HER-2 • ER • PIK3CA • BRCA1 • BRCA2","pipe":" | ","alterations":" ER positive • BRCA1 mutation • HER-2 negative • PIK3CA mutation","tags":["HER-2 • ER • PIK3CA • BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • BRCA1 mutation • HER-2 negative • PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • doxorubicin hydrochloride • cyclophosphamide • fulvestrant • triptorelin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 01/28/2021","start_date":" 01/28/2021","primary_txt":" Primary completion: 01/28/2023","primary_completion_date":" 01/28/2023","study_txt":" Completion: 01/28/2024","study_completion_date":" 01/28/2024","last_update_posted":"2021-02-15"},{"id":"0af14f05-1d93-4af4-87b3-45e60f921800","acronym":"GIADA","url":"https://clinicaltrials.gov/study/NCT04659551","created_at":"2021-01-19T20:42:16.905Z","updated_at":"2024-07-02T16:36:37.586Z","phase":"Phase 2","brief_title":"Neoadjuvant Chemo-endocrine Therapy and Immunotherapy for Pre-menopausal Luminal B Breast Cancer Patients","source_id_and_acronym":"NCT04659551 - GIADA","lead_sponsor":"Istituto Oncologico Veneto IRCCS","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cyclophosphamide • epirubicin • exemestane • triptorelin • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 43","initiation":"Initiation: 10/05/2017","start_date":" 10/05/2017","primary_txt":" Primary completion: 05/25/2020","primary_completion_date":" 05/25/2020","study_txt":" Completion: 05/25/2020","study_completion_date":" 05/25/2020","last_update_posted":"2020-12-09"}]